{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:42:52Z","timestamp":1791474172413,"version":"4.3.4"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003621","name":"MSIP","doi-asserted-by":"publisher","award":["MRC.2008-0062275"],"award-info":[{"award-number":["MRC.2008-0062275"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.pharmthera.2017.02.025","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T07:31:31Z","timestamp":1487057491000},"page":"127-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":151,"special_numbering":"C","title":["Interleukin 32, inflammation and cancer"],"prefix":"10.1016","volume":"174","author":[{"given":"Jin Tae","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Ju","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong Kil","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Young","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2017.02.025_bb0005","doi-asserted-by":"crossref","first-page":"R135","DOI":"10.1186\/ar3073","article-title":"Innate immunity triggers IL-32 expression by fibroblast-like synoviocytes in rheumatoid arthritis","volume":"12","author":"Alsaleh","year":"2010","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0010","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.18632\/oncotarget.7007","article-title":"IL-32\u03b8 inhibits stemness and epithelial-mesenchymal transition of cancer stem cells via the STAT3 pathway in colon cancer","volume":"7","author":"Bak","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0015","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1165\/rcmb.2013-0234OC","article-title":"Interleukin-32gamma suppresses allergic airway inflammation in mouse models of asthma","volume":"50","author":"Bang","year":"2014","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2249.2009.03920.x","article-title":"Differential expression of immunoregulatory genes in monocytes in response to Porphyromonas gingivalis and Escherichia coli lipopolysaccharide","volume":"156","author":"Barksby","year":"2009","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0025","first-page":"289","article-title":"Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine\/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes","volume":"16","author":"Cagnard","year":"2005","journal-title":"European Cytokine Network"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0030","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1164\/rccm.200804-646OC","article-title":"IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease","volume":"178","author":"Calabrese","year":"2008","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0035","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1172\/JCI200421032","article-title":"Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis","volume":"114","author":"Chan","year":"2004","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0083-6729(06)74008-0","article-title":"The newest interleukins: Recent additions to the ever-growing cytokine family","volume":"74","author":"Chen","year":"2006","journal-title":"Vitamins and Hormones"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0045","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.2147\/OTT.S103581","article-title":"Interleukin-32\u03b1 inactivates JAK2\/STAT3 signaling and reverses interleukin-6-induced epithelial\u2013mesenchymal transition, invasion, and metastasis in pancreatic cancer cells","volume":"9","author":"Chen","year":"2016","journal-title":"OncoTargets and Therapy"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0050","doi-asserted-by":"crossref","first-page":"12049","DOI":"10.1074\/jbc.M110.159756","article-title":"Overexpression of IL-32alpha increases natural killer cell-mediated killing through up-regulation of Fas and UL16-binding protein 2 (ULBP2) expression in human chronic myeloid leukemia cells","volume":"286","author":"Cheon","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bbrc.2010.09.099","article-title":"The effects of IL-32 on the inflammatory activation of cultured rat primary astrocytes","volume":"402","author":"Cho","year":"2010","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0060","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2567.2008.02917.x","article-title":"Identification of the most active interleukin-32 isoform","volume":"126","author":"Choi","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0065","doi-asserted-by":"crossref","first-page":"21082","DOI":"10.1073\/pnas.1015418107","article-title":"Paradoxical effects of constitutive human IL-32{gamma} in transgenic mice during experimental colitis","volume":"107","author":"Choi","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0070","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3892\/ol.2015.3950","article-title":"Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma","volume":"11","author":"Cui","year":"2016","journal-title":"Oncology Letters"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0075","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4049\/jimmunol.148.2.597","article-title":"Identification of a novel gene expressed in activated natural killer cells and T cells","volume":"148","author":"Dahl","year":"1992","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0080","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrd2783","article-title":"Unleashing the therapeutic potential of NOD-like receptors","volume":"8","author":"Geddes","year":"2009","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0085","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/intimm\/dxh339","article-title":"Involvement of IL-32 in activation-induced cell death in T cells","volume":"18","author":"Goda","year":"2006","journal-title":"International Immunology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0090","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cyto.2010.09.002","article-title":"Native IL-32 is released from intestinal epithelial cells via a non-classical secretory pathway as a membrane-associated protein","volume":"53","author":"Hasegawa","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0095","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1073\/pnas.1016005108","article-title":"Inflammation-dependent secretion and splicing of IL-32{gamma} in rheumatoid arthritis","volume":"108","author":"Heinhuis","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0100","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/ard.2010.139196","article-title":"Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade","volume":"70","author":"Heinhuis","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cyto.2013.05.002","article-title":"Towards a role of interleukin-32 in atherosclerosis","volume":"64","author":"Heinhuis","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0115","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1002\/ijc.23173","article-title":"Inflammation and cancer: An ancient link with novel potentials","volume":"121","author":"Hussain","year":"2007","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0120","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s12035-014-8739-0","article-title":"Reducing effect of IL-32alpha in the development of stroke through blocking of NF-kappaB, but enhancement of STAT3 pathways","volume":"51","author":"Hwang","year":"2015","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0125","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.vetimm.2010.04.019","article-title":"Cloning and characterization of bovine interleukin-32 beta isoform","volume":"137","author":"Jaekal","year":"2010","journal-title":"Veterinary Immunology and Immunopathology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0130","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1182\/blood-2004-09-3751","article-title":"The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis","volume":"105","author":"Jenkins","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0135","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/path.2899","article-title":"IL-32 up-regulation is associated with inflammatory cytokine production in allergic rhinitis","volume":"224","author":"Jeong","year":"2011","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0140","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1073\/pnas.0511233103","article-title":"IL-32, a proinflammatory cytokine in rheumatoid arthritis","volume":"103","author":"Joosten","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0145","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1111\/j.1365-2567.2008.03025.x","article-title":"A proinflammatory cytokine interleukin-32beta promotes the production of an anti-inflammatory cytokine interleukin-10","volume":"128","author":"Kang","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0150","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.biochi.2014.01.013","article-title":"Interaction network mapping among IL-32 isoforms","volume":"101","author":"Kang","year":"2014","journal-title":"Biochimie"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0155","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.canlet.2011.12.023","article-title":"Dysregulation of overexpressed IL-32alpha in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-kappaB and Bcl-2","volume":"318","author":"Kang","year":"2012","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0160","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev-immunol-030409-101225","article-title":"Inflammatory bowel disease","volume":"28","author":"Kaser","year":"2010","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0165","first-page":"865","article-title":"IL-32 is increased along with tryptase in lesional psoriatic skin and is up-regulated by substance P in human mast cells","volume":"20","author":"Kempuraj","year":"2010","journal-title":"European Journal of Dermatology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/ACI.0b013e32835b35d5","article-title":"Role of interleukin-32 in chronic rhinosinusitis","volume":"13","author":"Keswani","year":"2013","journal-title":"Current Opinion in Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0175","first-page":"131","article-title":"Interleukin-32: A cytokine and inducer of TNFalpha","volume":"22","author":"Kim","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0180","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/j.febslet.2014.06.029","article-title":"IL-32theta negatively regulates IL-1beta production through its interaction with PKCdelta and the inhibition of PU.1 phosphorylation","volume":"588","author":"Kim","year":"2014","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0185","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/art.27197","article-title":"Effect of interleukin-32gamma on differentiation of osteoclasts from CD14+ monocytes","volume":"62","author":"Kim","year":"2010","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0190","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jim.2007.12.017","article-title":"Interleukin-32 monoclonal antibodies for immunohistochemistry, Western blotting, and ELISA","volume":"333","author":"Kim","year":"2008","journal-title":"Journal of Immunological Methods"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0195","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cyto.2008.01.004","article-title":"Unique expression of a small IL-32 protein in the Jurkat leukemic T cell line","volume":"42","author":"Ko","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0200","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.cyto.2009.03.007","article-title":"Molecular characterization of IL-32 in human endothelial cells","volume":"46","author":"Kobayashi","year":"2009","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009458","article-title":"Interleukin-32beta propagates vascular inflammation and exacerbates sepsis in a mouse model","volume":"5","author":"Kobayashi","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0210","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/oby.21001","article-title":"Interleukin-32beta ameliorates metabolic disorder and liver damage in mice fed high-fat diet","volume":"23","author":"Lee","year":"2015","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0215","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1042\/CS20140576","article-title":"Interleukin-32gamma attenuates ethanol-induced liver injury by the inhibition of cytochrome P450 2E1 expression and inflammatory responses","volume":"128","author":"Lee","year":"2015","journal-title":"Clinical Science (London, England)"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0220","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2009.02.015","article-title":"Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors","volume":"15","author":"Lee","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0225","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2567.2010.03377.x","article-title":"Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene","volume":"132","author":"Lee","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0230","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3892\/ol.2011.511","article-title":"Overexpression of IL-32 is a novel prognostic factor in patients with localized clear cell renal cell carcinoma","volume":"3","author":"Lee","year":"2012","journal-title":"Oncology Letters"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0235","article-title":"Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection","volume":"3","author":"Li","year":"2008","journal-title":"PloS One"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0240","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.4049\/jimmunol.0902667","article-title":"IL-32: A host proinflammatory factor against influenza viral replication is upregulated by aberrant epigenetic modifications during influenza A virus infection","volume":"185","author":"Li","year":"2010","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0245","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1002\/cncr.25488","article-title":"MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer","volume":"116","author":"Majid","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0250","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1073\/pnas.0712391105","article-title":"Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function","volume":"105","author":"Marcondes","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"858\u2013865","key":"10.1016\/j.pharmthera.2017.02.025_bb0255","article-title":"IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis","volume":"125","author":"Meyer","year":"2010","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0260","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1053\/j.gastro.2007.11.055","article-title":"TNF receptor type I-dependent activation of innate responses to reduce intestinal damage-associated mortality","volume":"134","author":"Mizoguchi","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0265","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.bbapap.2006.07.002","article-title":"Protein sulfation analysis\u2014A primer","volume":"1764","author":"Monigatti","year":"2006","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0270","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/hep.24285","article-title":"Interleukin-32: A new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis","volume":"53","author":"Moschen","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0275","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/art.24299","article-title":"Tumor necrosis factor alpha-induced interleukin-32 is positively regulated via the Syk\/protein kinase Cdelta\/JNK pathway in rheumatoid synovial fibroblasts","volume":"60","author":"Mun","year":"2009","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0280","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s00415-011-6036-7","article-title":"Elevated serum level of interleukin-32alpha in the patients with myasthenia gravis","volume":"258","author":"Na","year":"2011","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0285","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1046\/j.1440-1746.2003.03034.x","article-title":"Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice","volume":"18","author":"Naito","year":"2003","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0290","doi-asserted-by":"crossref","first-page":"R120","DOI":"10.1186\/ar3850","article-title":"Enhanced susceptibility to lipopolysaccharide-induced arthritis and endotoxin shock in interleukin-32 alpha transgenic mice through induction of tumor necrosis factor alpha","volume":"14","author":"Nakayama","year":"2012","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0295","doi-asserted-by":"crossref","first-page":"16309","DOI":"10.1073\/pnas.0508237102","article-title":"IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism","volume":"102","author":"Netea","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030277","article-title":"Mycobacterium tuberculosis induces interleukin-32 production through a caspase- 1\/IL-18\/interferon-gamma-dependent mechanism","volume":"3","author":"Netea","year":"2006","journal-title":"PLoS Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0305","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/jso.24142","article-title":"IL-32\u03b1 has differential effects on proliferation and apoptosis of human melanoma cell lines","volume":"113","author":"Nicholl","year":"2016","journal-title":"Journal of Surgical Oncology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0310","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1046\/j.1432-1033.2003.03577.x","article-title":"The mystery of nonclassical protein secretion. A current view on cargo proteins and potential export routes","volume":"270","author":"Nickel","year":"2003","journal-title":"European Journal of Biochemistry"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0315","doi-asserted-by":"crossref","first-page":"17868","DOI":"10.1074\/jbc.M900368200","article-title":"Interleukin-32 expression in the pancreas","volume":"284","author":"Nishida","year":"2009","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0320","doi-asserted-by":"crossref","first-page":"G831","DOI":"10.1152\/ajpgi.00535.2007","article-title":"Phosphatidylinositol 3-kinase\/Akt signaling mediates interleukin-32alpha induction in human pancreatic periacinar myofibroblasts","volume":"294","author":"Nishida","year":"2008","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0325","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1073\/pnas.0813334106","article-title":"IL-32-dependent effects of IL-1beta on endothelial cell functions","volume":"106","author":"Nold-Petry","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0330","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4049\/jimmunol.1202802","article-title":"IL-32 promotes angiogenesis","volume":"192","author":"Nold-Petry","year":"2014","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0335","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1600-065X.2008.00648.x","article-title":"The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis","volume":"223","author":"Noss","year":"2008","journal-title":"Immunological Reviews"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0340","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1084\/jem.20090849","article-title":"TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis","volume":"207","author":"Noti","year":"2010","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0345","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1038\/onc.2011.52","article-title":"IL-32gamma inhibits cancer cell growth through inactivation of NF-kappaB and STAT3 signals","volume":"30","author":"Oh","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0350","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s13402-013-0154-4","article-title":"Interleukin-32\u03b2 stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway","volume":"36","author":"Park","year":"2013","journal-title":"Cellular Oncology (Dordrecht)"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0355","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.canlet.2014.10.030","article-title":"Hypoxia-induced IL-32\u03b2 increases glycolysis in breast cancer cells","volume":"356","author":"Park","year":"2015","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0360","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2567.2011.03513.x","article-title":"Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3","volume":"135","author":"Park","year":"2012","journal-title":"Immunology"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2017.02.025_bb0365","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1002\/mc.21990","article-title":"IL-32gamma enhances TNF-alpha-induced cell death in colon cancer","volume":"53","author":"Park","year":"2014","journal-title":"Molecular Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0370","doi-asserted-by":"crossref","first-page":"38566","DOI":"10.18632\/oncotarget.6160","article-title":"Decreased severity of collagen antibody and lipopolysaccharide-induced arthritis in human IL-32beta overexpressed transgenic mice","volume":"6","author":"Park","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0375","article-title":"Elevated interleukin-32 expression is associated with Helicobacter pylori-related gastritis","volume":"9","author":"Peng","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0380","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/carcin\/bgt092","article-title":"A promoter polymorphism in human interleukin-32 modulates its expression and influences the risk and the outcome of epithelial cell-derived thyroid carcinoma","volume":"34","author":"Plantinga","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0385","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1152\/japplphysiol.00872.2007","article-title":"Effects of 30min of aerobic exercise on gene expression in human neutrophils","volume":"104","author":"Radom-Aizik","year":"2008","journal-title":"Journal of Applied Physiology (1985)"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0390","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.imlet.2008.01.007","article-title":"Increased level of IL-32 during human immunodeficiency virus infection suppresses HIV replication","volume":"117","author":"Rasool","year":"2008","journal-title":"Immunology Letters"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0395","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1128\/IAI.00637-12","article-title":"Role of interleukin-32 in Helicobacter pylori-induced gastric inflammation","volume":"80","author":"Sakitani","year":"2012","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0400","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/carcin\/bgp272","article-title":"Inflammation and cancer: Interweaving microRNA, free radical, cytokine and p53 pathways","volume":"31","author":"Schetter","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0405","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/intimm\/dxn055","article-title":"Induction of pro-inflammatory programs in enteroendocrine cells by the Toll-like receptor agonists flagellin and bacterial LPS","volume":"20","author":"Selleri","year":"2008","journal-title":"International Immunology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0410","first-page":"1606","article-title":"Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining","volume":"18","author":"Seo","year":"2008","journal-title":"Journal of Microbiology and Biotechnology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0415","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1365-2249.2007.03439.x","article-title":"Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease","volume":"149","author":"Shioya","year":"2007","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0420","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/ar2074","article-title":"Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases","volume":"8","author":"Shoda","year":"2006","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0425","doi-asserted-by":"crossref","first-page":"6576","DOI":"10.4049\/jimmunol.1100277","article-title":"The immunosuppressive role of IL-32 in lymphatic tissue during HIV-1 infection","volume":"186","author":"Smith","year":"2011","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0430","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1164\/rccm.200903-0400OC","article-title":"Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype","volume":"180","author":"Sorrentino","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0435","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/jid.2013.488","article-title":"The role of IL-32 in cutaneous T-cell lymphoma","volume":"134","author":"Suga","year":"2014","journal-title":"The Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0440","doi-asserted-by":"crossref","first-page":"14444","DOI":"10.1073\/pnas.94.26.14444","article-title":"Generation of secretable and nonsecretable interleukin 15 isoforms through alternate usage of signal peptides","volume":"94","author":"Tagaya","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0445","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1158\/1078-0432.CCR-13-1221","article-title":"Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis","volume":"20","author":"Tsai","year":"2014","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0450","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3892\/ol.2014.2641","article-title":"IL-32 promotes breast cancer cell growth and invasiveness","volume":"9","author":"Wang","year":"2015","journal-title":"Oncology Letters"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0460","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s10875-012-9837-2","article-title":"Increased plasma interleukin-32 expression in patients with neuromyelitis optica","volume":"33","author":"Wang","year":"2013","journal-title":"Journal of Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0465","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jinf.2012.05.009","article-title":"Increased interleukin-32 expression in chronic hepatitis B virus-infected liver","volume":"65","author":"Xu","year":"2012","journal-title":"The Journal of Infection"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0470","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clim.2013.02.021","article-title":"IL-32 with potential insights into rheumatoid arthritis","volume":"147","author":"Xu","year":"2013","journal-title":"Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0475","first-page":"263","article-title":"Interleukin-32alpha expression in human colonic subepithelial myofibroblasts","volume":"27","author":"Yagi","year":"2011","journal-title":"International Journal of Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0480","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12957-015-0552-3","article-title":"Dysregulation of over-expressed IL-32 in colorectal cancer induces metastasis","volume":"13","author":"Yang","year":"2015","journal-title":"World Journal of Surgical Oncology"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0485","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cyto.2012.09.022","article-title":"Expression of IL-32 modulates NF-\u03baB and p38 MAP kinase pathways in human esophageal cancer","volume":"61","author":"Yousif","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0490","doi-asserted-by":"crossref","first-page":"40452","DOI":"10.18632\/oncotarget.6306","article-title":"Myelin oligodendrocyte glycoprotein (MOG35\u201355)-induced experimental autoimmune encephalomyelitis is ameliorated in interleukin-32 alpha transgenic mice","volume":"6","author":"Yun","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0495","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.166","article-title":"Antitumor activity of IL-32beta through the activation of lymphocytes, and the inactivation of NF-kappaB and STAT3 signals","volume":"4","author":"Yun","year":"2013","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0500","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/onc.2014.128","article-title":"Loss of presenilin 2 is associated with increased iPLA2 activity and lung tumor development","volume":"33","author":"Yun","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0505","doi-asserted-by":"crossref","first-page":"9061","DOI":"10.18632\/oncotarget.3197","article-title":"IL-32alpha suppresses colorectal cancer development via TNFR1-mediated death signaling","volume":"6","author":"Yun","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0510","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cyto.2013.09.017","article-title":"Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression","volume":"65","author":"Zeng","year":"2014","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0515","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3109\/02713683.2012.763102","article-title":"TLR-mediated induction of proinflammatory cytokine IL-32 in corneal epithelium","volume":"38","author":"Zhang","year":"2013","journal-title":"Current Eye Research"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0520","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.cellsig.2008.01.004","article-title":"Alteration in the activation state of new inflammation-associated targets by phospholipase A2-activating protein (PLAA)","volume":"20","author":"Zhang","year":"2008","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0525","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.cellsig.2009.02.018","article-title":"Phospholipase A2-activating protein (PLAA) enhances cisplatin-induced apoptosis in HeLa cells","volume":"21","author":"Zhang","year":"2009","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2017.02.025_bb0530","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.3892\/ijmm.2015.2159","article-title":"Interleukin-32 stimulates osteosarcoma cell invasion and motility via AKT pathway-mediated MMP-13 expression","volume":"35","author":"Zhou","year":"2015","journal-title":"International Journal of Molecular Medicine"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725817300396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725817300396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T09:19:20Z","timestamp":1719047960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725817300396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":104,"alternative-id":["S0163725817300396"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.025","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin 32, inflammation and cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}